Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 7/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15354765 | 1.00 | PDK2 (0.46) | PDK2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27956065 | 0.92 | HTR1A (0.41) | PDK2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2084224 | 0.90 | CYP11B2 (0.43) | PDK2HTR1ASLC6A2SLC6A4CHRNB2 | |
| SCHEMBL27653913 | 0.87 | HTR1A (0.58) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL29353268 | 0.85 | HTR6 (0.46) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL27786686 | 0.85 | HTR2C (0.59) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| Hydrochloric Acid SCHEMBL15286770 | 0.85 | HTR2C (0.59) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL26971374 | 0.85 | HTR6 (0.46) | CHRNB2CHRNA4CHRNB1CHRNB4CHRNA3 | |
| SCHEMBL29889413 | 0.80 | HTR1A (0.49) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL15286661 | 0.79 | MEN1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK2A3, CSNK1G1 | PDK2 1941/4885HTR1A 2702/4885SLC6A2 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.